Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 8.32 is in line with its 5-year average of 9.23, near the low end of its 5-year range (2.37–26.10).
As of the fiscal period ended Tuesday, June 30, 2026. 11.12% below its 12-month average of 9.36.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 8.32.
QUICK RATIO (ACID-TEST)
8.32
QUICK RATIO (ACID-TEST) AVG TTM
9.36
QUICK RATIO (ACID-TEST) AVG 3Y
10.73
QUICK RATIO (ACID-TEST) AVG 5Y
9.23
QUICK RATIO (ACID-TEST) AVG 10Y
11.22
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
-11.12%
CURRENT VS 3Y AVG
-22.43%
CURRENT VS 5Y AVG
-9.85%
CURRENT VS 10Y AVG
-25.84%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.35
median of 871 covered companies
CURRENT VS SECTOR MEDIAN
+148.46%
vs the sector median at left
Denali Therapeutics Inc.
Market Cap
$3.11B
Quick Ratio (Acid-Test)
8.32
TTM Avg
9.36
3Y Avg
10.73
5Y Avg
9.23
Market Cap
$3.09B
Quick Ratio (Acid-Test)
12.12
TTM Avg
10.47
3Y Avg
8.53
5Y Avg
7.00
Market Cap
$3.03B
Quick Ratio (Acid-Test)
2.67
TTM Avg
3.48
3Y Avg
6.28
5Y Avg
8.36
Market Cap
$3.19B
Quick Ratio (Acid-Test)
3.17
TTM Avg
4.10
3Y Avg
7.42
5Y Avg
12.78
Market Cap
$3.00B
Quick Ratio (Acid-Test)
64.07
TTM Avg
24.32
3Y Avg
16.73
5Y Avg
16.77
Market Cap
$3.33B
Quick Ratio (Acid-Test)
4.72
TTM Avg
21.21
3Y Avg
17.30
5Y Avg
19.05
Market Cap
$3.33B
Quick Ratio (Acid-Test)
17.91
TTM Avg
1.68
3Y Avg
1.68
5Y Avg
1.68
Market Cap
$2.84B
Quick Ratio (Acid-Test)
12.02
TTM Avg
18.93
3Y Avg
12.46
5Y Avg
15.83
Market Cap
$3.39B
Quick Ratio (Acid-Test)
3.30
TTM Avg
3.01
3Y Avg
3.08
5Y Avg
4.22
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | $3.11B | 8.32 | 9.36 | 10.73 | 9.23 |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.09B | 12.12 | 10.47 | 8.53 | 7.00 |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $3.03B | 2.67 | 3.48 | 6.28 | 8.36 |
| Tarsus Pharmaceuticals, Inc. (TARS)vs › | $3.19B | 3.17 | 4.10 | 7.42 | 12.78 |
| Enliven Therapeutics, Inc. (ELVN)vs › | $3.00B | 64.07 | 24.32 | 16.73 | 16.77 |
| Viking Therapeutics, Inc. (VKTX)vs › | $3.33B | 4.72 | 21.21 | 17.30 | 19.05 |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.33B | 17.91 | 1.68 | 1.68 | 1.68 |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.84B | 12.02 | 18.93 | 12.46 | 15.83 |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.39B | 3.30 | 3.01 | 3.08 | 4.22 |
| CareDx, Inc (CDNA)vs › | $3.40B | 4.51 | 3.14 | 3.73 | 4.01 |
Quick Ratio
8.32
Excludes inventory
Current Ratio
8.37
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 8.32 |
| 2026-03-31 | 9.28 |
| 2025-12-31 | 9.16 |
| 2025-09-30 | 9.79 |
| 2025-06-30 | 10.27 |
| 2025-03-31 | 9.56 |
| 2024-12-31 | 8.46 |
| 2024-09-30 | 9.98 |
| 2024-06-30 | 12.46 |
| 2024-03-31 | 11.79 |
| 2023-12-31 | 13.65 |
| 2023-09-30 | 16.06 |
| 2023-06-30 | 17.65 |
| 2023-03-31 | 3.39 |
| 2022-12-31 | 3.77 |
| 2022-09-30 | 3.16 |
| 2022-06-30 | 3.20 |
| 2022-03-31 | 2.90 |
| 2021-12-31 | 2.37 |
| 2021-09-30 | 19.46 |
| 2021-06-30 | 26.10 |
| 2021-03-31 | 26.22 |
| 2020-12-31 | 20.86 |
| 2020-09-30 | 9.21 |
| 2020-06-30 | 9.57 |
| 2020-03-31 | 12.70 |
| 2019-12-31 | 9.48 |
| 2019-09-30 | 10.59 |
| 2019-06-30 | 10.66 |
| 2019-03-31 | 11.55 |
| 2018-12-31 | 14.93 |
| 2018-09-30 | 12.13 |
| 2018-06-30 | 12.17 |
| 2018-03-31 | 21.99 |
| 2017-12-31 | 28.95 |
| 2017-09-30 | 18.54 |
| 2017-06-30 | 17.55 |
| 2017-03-31 | 0.00 |
| 2016-12-31 | 20.03 |
| 2016-09-30 | 0.00 |
| 2016-06-30 | 0.00 |
| 2016-03-31 | 0.00 |
